New: our quarterly report on the S&P 500, read from 500 companies’ own filings and calls.
Read the Q3 2026 report
Friday, Nov 20, 2026
Export WST’s income statement to Excel — free account
West Pharmaceutical Services, Inc.
WSTHealthcare Medical Instruments & Supplies
West Pharmaceutical Services, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $3.1 billion, up 6.25% from fiscal 2024.
- Revenue
- +8.69%
- EPS
- +57.3%
- Free cash flow
- +12.3%
- Total debt
- +0.10%
Quarter to September 2026, against a year earlier
390.56
6.13
−1.55%
After hours trading: 390.30, down 0.07%, last trade 5:54pm Eastern.
Follow WST
Alert me
Revenue to profit Q3 FY2026, quarter to Sep 30, 2026
Of every $100 of revenue, $24.47 was left as profit. Gross margin has risen two quarters running, from 35.1% to 39.7%. What is an income statement?
| Revenue | 874.5 | 100.0% |
|---|---|---|
| Cost of revenue | −527.1 | −60.3% |
| Gross profit | 347.4 | 39.7% |
| Research & development | −18.3 | −2.1% |
| Selling, general & admin | −112.9 | −12.9% |
| Other operating costs | +51.2 | 5.9% |
| Operating income | 267.4 | 30.6% |
| Income tax | −58.0 | −6.6% |
| Other items | +4.3 | 0.5% |
| Net income | 214.0 | 24.5% |
Net margin (right axis)
| Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | |
|---|---|---|---|---|
| Revenue | $805M | $845M | $872M | $874M |
| Operating income | $157M | $177M | $179M | $267M |
| Net income | $132M | $139M | $154M | $214M |
| Net margin (right axis) | 16.4% | 16.4% | 17.7% | 24.5% |
| Older periods | Dec '25 | Mar '26 | Jun '26 | Sep '26 | |
|---|---|---|---|---|---|
Revenue |
+8 more quarters Free account |
805.00 | 844.90 | 872.30 | 874.50 |
Revenue Growth |
7.51% | 21.05% | 13.80% | 8.69% | |
Cost of Revenue |
501.10 | 548.50 | 543.10 | 527.10 | |
Gross Profit |
303.90 | 296.40 | 329.20 | 347.40 | |
R&D Expenses |
21.80 | 15.80 | 19.70 | 18.30 | |
SG&A Expenses |
107.00 | 99.50 | 117.60 | 112.90 | |
Operating Income |
156.60 | 177.10 | 179.10 | 267.40 | |
Non-operating Interest Expenses |
(0.20) | 1.90 | 2.60 | 3.80 | |
Non-operating Income/Expense |
4.90 | 3.00 | 1.00 | 0.30 | |
| 161.50 | 180.10 | 180.10 | 267.70 | ||
Income Tax Provision |
33.30 | 44.70 | 32.20 | 58.00 | |
Income after Tax |
128.20 | 135.40 | 147.90 | 209.70 | |
Share of Subsidiary Earnings |
3.90 | 3.40 | 6.10 | 4.30 | |
Net Income Common |
132.10 | 138.80 | 154.00 | 214.00 | |
EPS (Basic) |
1.83 | 1.93 | 2.17 | 3.04 | |
EPS (Diluted) |
1.82 | 1.92 | 2.15 | 3.02 | |
Shares (Basic, Weighted) |
72.30 | 72.00 | 70.80 | 70.40 | |
Shares (Diluted, Weighted) |
72.70 | 72.40 | 71.30 | 70.80 | |
Gross Margin |
37.75% | 35.08% | 37.74% | 39.73% | |
EBIT Margin |
19.45% | 20.96% | 20.53% | 30.58% | |
EBT margin |
20.06% | 21.32% | 20.65% | 30.61% | |
Net Profit Margin |
16.41% | 16.43% | 17.65% | 24.47% | |
EBITDA |
203.60 | 222.30 | 225.30 | 313.30 | |
EBIT |
156.60 | 177.10 | 179.10 | 267.40 | |
Income from Continuous Operations |
132.10 | 138.80 | 154.00 | 214.00 | |
Consolidated Net Income/Loss |
132.10 | 138.80 | 154.00 | 214.00 | |
EPS (Basic, from Continuous Ops) |
1.83 | 1.93 | 2.18 | 3.04 | |
EPS (Diluted, from Cont. Ops) |
1.81 | 1.92 | 2.16 | 3.02 | |
EPS (Basic, Consolidated) |
1.83 | 1.93 | 2.18 | 3.04 | |
EPS (Diluted, Consolidated) |
1.81 | 1.92 | 2.16 | 3.02 | |
Shares (Diluted, Average) |
72.70 | 72.40 | 71.30 | 70.80 | |
EBITDA Margin |
25.29% | 26.31% | 25.83% | 35.83% | |
Operating Cash Flow Margin |
31.19% | 10.64% | 14.22% | 21.67% |
In millions of $ except per-share values · columns are period end dates · fundamentals updated Nov 18, 2026